U.S. Transportation Stock News

BILL Holdings recently launched Bill Travel, integrating travel booking, budgets, card controls, and expense management into its Bill Spend & Expense platform to give businesses a single, connected workflow for managing one of their largest and least controlled cost categories. The company is also rolling out AI-driven automation, expanded international capabilities, and customizable cards, signaling a push to deepen its role in small and midsize business spend management operations. We’ll...

Trimble (TRMB) is drawing attention after doubling down on its AI push by integrating Anthropic's Claude into SketchUp and agreeing to acquire Document Crunch, an AI firm focused on construction document analysis. See our latest analysis for Trimble. Recent AI announcements and analyst commentary have arrived alongside a 5.13% 1 month share price return. The share price is still down 12.65% year to date, while the 3 year total shareholder return sits at 42.39%. This suggests longer term...

In April 2026, ACI Worldwide and Kinexys by J.P. Morgan integrated Liink’s Confirm application into ACI’s Fraud and Financial Crime solution, while ACI also rolled out its cloud-native ACI Connetic platform connecting eight major U.S. payment networks and embedding cross-rail fraud controls. Together, these moves deepen ACI’s role at the center of real-time, multi-rail payments and fraud prevention, simplifying compliance as transaction complexity grows. We’ll now examine how the expanded...

Casey's General Stores (CASY) has put menu innovation in the spotlight again by reintroducing its most requested limited time Bacon Cheeseburger Pizza and adding Crispy Fries as a permanent side, drawing fresh attention from customers and investors. See our latest analysis for Casey's General Stores. The share price has climbed to US$835.92, with a 30 day share price return of 13.40% and a 50.28% year to date share price return. The 1 year total shareholder return of 82.95% and 5 year total...

Altria Group (MO) opened 2026 with Q1 revenue of US$5.4b and basic EPS of US$1.30, setting a clear marker for how its cash generative tobacco portfolio is currently performing. Over recent quarters, the company has seen revenue shift from US$5.1b in Q4 2024 to US$4.5b in Q1 2025 and then to US$5.1b in Q4 2025. Quarterly basic EPS moved from US$1.79 to US$0.64 and then to US$0.66, giving investors a detailed view of how earnings per share track against the top line. With trailing net profit...

What triggered Sigma Lithium’s latest move? The recent jump in Sigma Lithium (SGML) shares centers on a $50 million prepayment agreement that eased short term liquidity pressure and was quickly followed by a major analyst upgrade on April 2, 2026. See our latest analysis for Sigma Lithium. That prepayment deal and upgrade came after a very sharp shift in sentiment, with a 30 day share price return of 85.71% and a 1 year total shareholder return of 165.02%, contrasting with a weaker 3 year...

Virtus Investment Partners (VRTS) has just put fresh numbers on the table, reporting Q4 2025 revenue of US$208.0 million and basic EPS of US$5.25. These results are backed by trailing 12 month revenue of US$852.9 million and EPS of US$20.27. Over the past year, revenue has moved from US$906.9 million to US$852.9 million on a trailing basis, while EPS shifted from US$17.19 to US$20.27. This provides a basis for investors to weigh recent earnings against the longer track record. With net income...

If you are wondering whether Kyivstar Group's current share price lines up with its underlying value, this article will walk through the key numbers that matter. The stock recently closed at US$12.29, with returns of 4.9% over the last week, 20.8% over the last month, and 0.7% over the past year. Year to date it is down 7.4%. Recent price moves sit against a backdrop of ongoing attention on Kyivstar Group and its position in the Wireless Telecom space, with investors weighing how the current...

Culper Research’s recent report accusing ADMA Biologics (ADMA) of inflating reported growth through its distribution practices, along with the subsequent Pomerantz LLP securities investigation, has quickly become the main focus for shareholders. See our latest analysis for ADMA Biologics. The Culper report and related legal scrutiny arrived after a sharp reset in sentiment, with the share price showing a 15.48% 1 month gain to US$10.52 but a 39.19% 3 month and 41.16% year to date share price...

In April 2026, Amentum announced Joseph (Joe) DeNardi as Senior Vice President and Head of Investor Relations, succeeding Nathan Rutledge, while also highlighting its critical ground systems role in NASA’s Artemis II crewed mission at Kennedy Space Center. This combination of leadership change and high-visibility Artemis II support underscores how Amentum is sharpening its investor engagement while showcasing its operational capabilities in complex space programs. Next, we’ll examine how...

Record revenue, new contracts and board changes set the stage Centuri Holdings (CTRI) recently reported record annual revenue above US$3b, outlined its outlook for 2026, secured over US$870m in new North American awards, and added new independent directors to its board. See our latest analysis for Centuri Holdings. The strong operating update sits alongside a 30 day share price return of 29.24% and a year to date share price return of 52.01%, while a 1 year total shareholder return of 111.25%...

Viasat (VSAT) shares recently reacted to the successful launch and initial signal acquisition of the ViaSat 3 Flight 3 satellite, which completes the company’s next generation constellation serving the Asia Pacific region. See our latest analysis for Viasat. Against this backdrop, the recent ViaSat 3 F3 launch and new defense and airline connectivity wins come after a sharp run, with a 73.1% year to date share price return and very large 1 year total shareholder return. If you are looking...

Paychex, Inc. recently announced that its Board of Directors approved a 10% increase to the regular quarterly cash dividend to US$1.19 per share, marking the fifth consecutive double-digit hike and continuing a dividend record that dates back to 1988. The company also plans to return over US$1.50 billion in dividends to shareholders for the fiscal year ending May 31, 2026, underscoring a long-term commitment to cash returns alongside its human capital management growth initiatives. Next,...

In late April 2026, CareTrust REIT completed a sale‑leaseback acquisition of 15 skilled nursing facilities in California and added healthcare properties in the UK and Wyoming, while also originating new loans secured by skilled nursing portfolios. This expansion deepens CareTrust REIT’s concentration in skilled nursing and broadens its geographic footprint, potentially affecting tenant mix, risk exposure, and portfolio resilience. We’ll now examine how this expansion of skilled nursing...

In April 2026, BeOne Medicines reported that the FDA granted Priority Review to its sBLA for TEVIMBRA plus ZIIHERA and chemotherapy, and Breakthrough Therapy Designation for ZIIHERA-based regimens, for first-line treatment of unresectable locally advanced or metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma. The Phase 3 HERIZON-GEA-01 trial underpinning these filings showed statistically significant gains in overall and progression-free survival versus...

If you are wondering whether Laureate Education's current share price lines up with its underlying worth, this article walks through what the numbers are really saying about value. The stock last closed at US$31.24, with returns of 0.8% over 7 days, a 6.9% decline over 30 days, a 6.2% decline year to date, and a 40.2% return over 1 year. These moves sit against a backdrop of ongoing coverage of Laureate Education's position in the education services space and investor interest in how well...

Crinetics Pharmaceuticals announced that the European Commission has approved PALSONIFY (paltusotine), the first once-daily oral SST2 agonist, for treating adult acromegaly across the EU and EEA, based on Phase 3 PATHFNDR data showing biochemical and symptom control with a generally well-tolerated safety profile. This approval, coupled with PALSONIFY’s Orphan Drug Designation in the EU and initial commercialization plans in Germany and Austria, expands Crinetics’ addressable acromegaly...

Stoke Therapeutics (STOK) has drawn fresh investor attention after recent share price moves, with the stock showing mixed short term performance and gains over the past 3 months and year. See our latest analysis for Stoke Therapeutics. At a share price of $33.08, Stoke Therapeutics has seen a 1 day share price return of 1.10%, while its 1 year total shareholder return of 243.51% reflects recent momentum following a slower multi year record. If you are comparing Stoke with other high growth...

nVent Electric (NVT) just reported first quarter results that put fresh numbers behind the recent excitement around the stock, with higher sales, detailed earnings figures, and upbeat analyst commentary drawing investor attention. See our latest analysis for nVent Electric. The strong first quarter update comes on top of powerful recent momentum, with a 31.06% 1 month share price return and a 168.68% 1 year total shareholder return pointing to rising optimism about nVent Electric’s role in...

Defiance ETFs has launched the Defiance Daily Target 2X Long POET ETF (ticker: POEL). POEL is designed to provide 2X daily leveraged exposure to POET Technologies shares (NasdaqCM:POET). This is the first leveraged ETF focused specifically on POET Technologies. POET Technologies, listed on NasdaqCM:POET, operates in the semiconductor and photonics space, an area that has drawn strong interest as data centers, AI workloads, and high speed connectivity needs expand. The launch of POEL adds a...

Stride (LRN) is back in focus after reporting third quarter and nine month 2026 results that showed higher sales, mixed profit trends, and fresh guidance that narrows the company’s full year revenue and operating income ranges. See our latest analysis for Stride. The latest earnings and guidance arrived after a strong run in the share price, with a year to date share price return of 44.06% and a 3 year total shareholder return of 126.03%. This contrasts sharply with a 1 year total shareholder...

Opendoor Technologies (OPEN) is back in focus after fresh analyst coverage, a surge in options activity, and rising social media interest, all converging ahead of the company’s May 7 earnings release. See our latest analysis for Opendoor Technologies. The share price has been volatile, with a 19.04% 1 month share price return and a 5.63% 3 month share price return, while the year to date share price return is a 10.38% decline. However, the 1 year total shareholder return is very large at...

InterDigital (IDCC) is back on investor radar after Q1 2026 results exceeded the company’s own guidance for revenue, adjusted EBITDA, and EPS, supported by fresh licensing deals with Xiaomi, LG, and Sony. See our latest analysis for InterDigital. Despite Q1 results landing ahead of guidance and fresh licensing wins, the 7 day share price return of 21.17% and year to date share price return of 10.96% both point to fading short term momentum, while the 5 year total shareholder return of 342.02%...

BOK Financial (BOKF) caught investor attention after reporting first quarter results that contrasted with its slower long term growth profile, with both net interest income and net income higher than a year earlier. See our latest analysis for BOK Financial. The recent earnings release and confirmation that the current buyback program has already retired almost 3.0 million shares come after a strong run, with the share price at $133.51 and a year to date share price return of 12.5%. Over a...